Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc WT (ADILW)

Adial Pharmaceuticals Inc WT (ADILW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,120 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ADILW with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/17/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.39
  • Number of Estimates 1
  • High Estimate -0.39
  • Low Estimate -0.39
  • Prior Year -1.33
  • Growth Rate Est. (year over year) +70.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0004 +125.00%
on 07/25/23
0.0148 -93.92%
on 07/12/23
-0.0049 (-84.48%)
since 06/27/23
3-Month
0.0004 +125.00%
on 07/25/23
0.0487 -98.15%
on 05/11/23
-0.0362 (-97.57%)
since 04/21/23
52-Week
0.0004 +125.00%
on 07/25/23
0.1990 -99.55%
on 08/01/22
-0.0391 (-97.75%)
since 07/27/22

Most Recent Stories

More News
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder

Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley

CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial

Expects Release of Top-Line Data in July...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial

Expects Release of Top-Line Data in July...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH

CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th

CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

ADIL : 1.2000 (-1.64%)
ADILW : 0.0009 (-57.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

3rd Resistance Point 0.0019
2nd Resistance Point 0.0017
1st Resistance Point 0.0013
Last Price 0.0009
1st Support Level 0.0007
2nd Support Level 0.0005
3rd Support Level 0.0001

See More

52-Week High 0.1990
Fibonacci 61.8% 0.1231
Fibonacci 50% 0.0997
Fibonacci 38.2% 0.0763
Last Price 0.0009
52-Week Low 0.0004

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar